Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Biora Therapeutics, Inc.

Biora Therapeutics is reimagining therapeutics by creating smart pills designed for 
- targeted drug delivery to the GI tract, and 
- systemic, needle-free delivery of biotherapeutics
we are developing therapies to improve patients’ lives. 

At Biora, we envision a world where patients have access to needle-free drug delivery and better therapeutic outcomes. We welcome you to learn more about our mission and our guiding principles at https://bioratherapeutics.com/company/about

Biora Therapeutics

Biora Therapeutics Q3 corporate update to be held on November 13: https://lnkd.in/dm7wYB5J

Biora Therapeutics presents new data on the BioJet platform at #EASD2023 https://lnkd.in/gfRHf8gJ 
#drugdelivery

Biora Therapeutics announces submission of IND application to the FDA for BT-600 program https://lnkd.in/d26etYKu #IBD #UC #ulcerativecolitis

Dr. Shaoying Nikki Lee presented data from the NaviCap™ targeted oral delivery platform to IBD researchers at the Crohn's & Colitis Foundation Researcher Symposium in New York City this week. #IBD #ulcerativecolitis #drugdelivery

Biora Therapeutics progresses its BioJet™ systemic oral delivery platform https://lnkd.in/gx8NfFwz #oraldelivery #biologics #needlefree #drugdelivery

Biora Therapeutics provides corporate update and reports second quarter 2023 financial results: https://lnkd.in/gQWCHdKe

Announcing successful clinical device performance study results for our NaviCap™ targeted oral delivery platform #IBD #UC #ulcerativecolitis  https://lnkd.in/e7fqQSvx

See this week's feature in the San Diego Business Journal highlighting our BioJet™ systemic delivery platform: https://lnkd.in/gYDTAWDK #oraldelivery #biologics #needlefree
#drugdelivery

Biora Therapeutics announces new patents for its NaviCap™ targeted oral delivery platform  https://lnkd.in/gpD-xZnf #IP

Congrats to the authors who were at the American Diabetes Association sharing bioavailability data for orally-delivered GLP-1 receptor agonist. If you haven't seen the poster yet, download it here:  https://lnkd.in/gR_S6biY #ADA2023 #oraldelivery #biologics #needlefree
#drugdelivery

NASDAQ:BIOR

Biora Therapeutics, Inc.

Last Close

2.64

08/11 21:00

Market Cap

23.40M

Beta: 1.26

Volume Today

64.65K

Avg: 184.13K

PE Ratio

−0.11

PFCF: −0.53

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics